Patent application number | Description | Published |
20080262919 | SYSTEM AND METHOD FOR FLEXIBLE PAYMENT TERMS - A method is disclosed for offering transaction account consumers with payment term options to pay a minimum amount due early, defer payment into the following payment cycle, and pay a standard amount when due. When generating a periodic billing statement, the invention determines a consumer's eligibility to elect early payment, deferred payment, and regular payment. When a consumer is eligible for early payment, a received payment is compared to a discount rate tier, then a discount amount is calculated and credited to the consumer's account. When the consumer is eligible for deferred payment, the system calculates a new current minimum payment due by multiplying the current non-deferred balance by a predetermined percentage amount and adding the result to the deferred balance. When the consumer is not eligible for deferred payment, the system calculates a new current minimum due by summing the current non-deferred balance with the deferred balance. | 10-23-2008 |
20090254478 | SYSTEM AND METHOD FOR FLEXIBLE DEFERRED PAYMENT TERMS - A method is disclosed for offering transaction account consumers with payment term options to pay a minimum amount due early, defer payment into the following payment cycle, and pay a standard amount when due. When generating a periodic billing statement, the invention determines a consumer's eligibility to elect early payment, deferred payment, and regular payment. When a consumer is eligible for early payment, a received payment is compared to a discount rate tier, then a discount amount is calculated and credited to the consumer's account. When the consumer is eligible for deferred payment, the system calculates a new current minimum payment due by multiplying the current non-deferred balance by a predetermined percentage amount and adding the result to the deferred balance. When the consumer is not eligible for deferred payment, the system calculates a new current minimum due by summing the current non-deferred balance with the deferred balance. | 10-08-2009 |
20090259548 | SYSTEM AND METHOD FOR FLEXIBLE ELECTION OF PAYMENT TERMS - A method is disclosed for offering transaction account consumers with payment term options to pay a minimum amount due early, defer payment into the following payment cycle, and pay a standard amount when due. When generating a periodic billing statement, the invention determines a consumer's eligibility to elect early payment, deferred payment, and regular payment. When a consumer is eligible for early payment, a received payment is compared to a discount rate tier, then a discount amount is calculated and credited to the consumer's account. When the consumer is eligible for deferred payment, the system calculates a new current minimum payment due by multiplying the current non-deferred balance by a predetermined percentage amount and adding the result to the deferred balance. When the consumer is not eligible for deferred payment, the system calculates a new current minimum due by summing the current non-deferred balance with the deferred balance. | 10-15-2009 |
20140136406 | SYSTEM AND METHOD FOR FLEXIBLE PAYMENT TERMS - A method is disclosed for offering transaction account consumers with payment term options to pay a minimum amount due early, defer payment into the following payment cycle, and pay a standard amount when due. When generating a periodic billing statement, the invention determines a consumer's eligibility to elect early payment, deferred payment, and regular payment. When a consumer is eligible for early payment, a received payment is compared to a discount rate tier, then a discount amount is calculated and credited to the consumer's account. When the consumer is eligible for deferred payment, the system calculates a new current minimum payment due by multiplying the current non-deferred balance by a predetermined percentage amount and adding the result to the deferred balance. When the consumer is not eligible for deferred payment, the system calculates a new current minimum due by summing the current non-deferred balance with the deferred balance. | 05-15-2014 |
Patent application number | Description | Published |
20090047301 | Papillomavirus L2 N-Terminal Peptides for the Induction of Broadly Cross-Neutralizing Antibodies - The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide. | 02-19-2009 |
20090203113 | CHIMERIC PAPILLOMAVIRUS-LIKE PARTICLES - The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines. | 08-13-2009 |
20100135902 | PAPILLOMAVIRUS PSEUDOVIRUSES FOR DETECTION AND THERAPY OF TUMORS - Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP) | 06-03-2010 |
20100166707 | EXTRACELLULAR MATRIX/METASTASIS MODIFIER GENES FOR THE PREVENTION OR INHIBITION OF METASTASIS OR GROWTH OF TUMOR AND FOR CHARACTERIZATION OF TUMOR - Disclosed are methods involving the administration of an extracellular matrix (ECM)/metastasis modifier gene, e.g., Anakin, Necdin, CentaurinD3 (CentD3), Csf1r, Brd4, Pi16, and Luc7l, for the prevention or inhibition of metastasis or of tumor growth. Further disclosed are methods of characterizing a tumor or cancer in a subject comprising detecting (i) a single nucleotide polymorphism (SNP) in an Anakin gene or a Brd4 gene of the subject, (ii) an amino acid substitution in an Anakin protein in the subject, or (iii) a level of expression of an Anakin gene or a Brd4 gene in the subject. Methods of screening a compound for anti-cancer activity and use of a compound with anti-cancer activity for the preparation of a medicament to treat or prevent cancer in a subject are also disclosed. Also disclosed is a method of inhibiting Sipa-1 in a subject. | 07-01-2010 |
20100172936 | CHIMERIC PAPILLOMAVIRUS-LIKE PARTICLES - The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines. | 07-08-2010 |
20130177585 | PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES - The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide. | 07-11-2013 |
20130230456 | PAPILLOMAVIRUS PSEUDOVIRUSES FOR DETECTION AND THERAPY OF TUMORS - Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP) | 09-05-2013 |
Patent application number | Description | Published |
20090074752 | Surrogate Therapeutic Endpoint For Anti-CTLA-4 Based Immunotherapy Of Disease - The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. | 03-19-2009 |
20100233181 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 09-16-2010 |
20100233182 | Antibodies against Clostridium difficile toxins and uses thereof - Antibodies that specifically bind to toxins of | 09-16-2010 |
20120100101 | CTLA-4 ANTIBODY DOSAGE ESCALATION REGIMENS - A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre-determined maximum dosage is reached. | 04-26-2012 |
20120114662 | HUMAN MONOCLONAL ANTIBODIES AGAINST BACILLUS ANTHRACIS PROTECTIVE ANTIGEN - Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. | 05-10-2012 |
20120288508 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 11-15-2012 |
20130129722 | Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 05-23-2013 |
20130230531 | Human Antibodies to Clostridium difficile Toxins - The present invention provides fully human antibodies that bind to either toxin A or toxin B of | 09-05-2013 |
20140120614 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 05-01-2014 |
20140221625 | B CELL LINEAGE BASED IMMUNOGEN DESIGN WITH HUMANIZED ANIMALS - Non-human animals with humanized immunoglobulin loci and methods of using them in vaccine design are described, as well as methods for making broadly neutralizing antibodies against infectious agents and pathogens are provided. Non-human animals with humanized immunoglobulin loci used in B-cell-lineage immunogen design in vaccine development are provided, as are methods of carrying out such design. | 08-07-2014 |
20150147342 | Methods for Treating Cancer by Administering an Anti-Ang-2 Antibody - The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis. | 05-28-2015 |